Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Completed

• Conditions: Systemic Aspergillosis; Systemic Candidiasis

• Registration Number: NCT01040156
• Lead Sponsor: University Children's Hospital Tuebingen

Brief Summary

Pediatric patients are at high risk to acquire mycotic infections following allogeneic bone marrow transplantation. In the present retrospective analysis we assess the safety and efficacy of different regimens in antimycotic prophylaxis.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-08
• Status Verified: 2009-12
• Primary Completion: 2009-12
• Study Completion: 2009-12
• Study First Submitted: 2009-12-28
• Study First Submitted QC: 2009-12-28
• Last Update Submitted: 2009-12-28
• Study First Posted: 2009-12-29
• Last Update Posted: 2009-12-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Pediatric patients under the age of 18 years
• Pediatric patients after HSCT treated with caspofungin
• Pediatric patients after HSCT treated with liposomal amphotericin

Exclusion Criteria

• Pediatric patients with uncontrolled hematological malignancies
• Pediatric patients with IFI at start of HSCT

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

University Children's Hospital; 🇩🇪 Tuebingen, Germany